Munsiff S S, Joseph S, Ebrahimzadeh A, Frieden T R
City of New York Department of Health, New York 10007, USA.
Clin Infect Dis. 1997 Dec;25(6):1465-7. doi: 10.1086/516146.
All New York City patients whose cultures yielded Mycobacterium tuberculosis with isolated resistance to rifampin in 1993 and 1994 were included in this study. Of the 96 patients, 48 (50%) had primary resistance, 32 (33%) had acquired resistance, and 16 (17%) had unclassified resistance; 66% had histories of illicit drug use, and 79% were infected with human immunodeficiency virus (HIV). The median time to emergence of resistance was 40 weeks among the 32 patients with acquired resistance. Each of the HIV-infected patients with acquired resistance (cases, n = 29) was matched to two HIV-infected patients who had disease due to fully susceptible M. tuberculosis (controls, n = 58). In multivariate analysis, factors associated with the emergence of rifampin resistance were as follows: a sputum smear positive for acid-fast bacilli, advanced immunosuppression, and nonadherence to therapy.
本研究纳入了1993年和1994年纽约市所有培养出对利福平具有单独耐药性的结核分枝杆菌的患者。在这96名患者中,48名(50%)为原发性耐药,32名(33%)为获得性耐药,16名(17%)为未分类耐药;66%有非法药物使用史,79%感染了人类免疫缺陷病毒(HIV)。在32名获得性耐药患者中,耐药出现的中位时间为40周。每例获得性耐药的HIV感染患者(病例组,n = 29)与两名因对结核分枝杆菌完全敏感而患病的HIV感染患者(对照组,n = 58)进行匹配。在多变量分析中,与利福平耐药出现相关的因素如下:痰涂片抗酸杆菌阳性、严重免疫抑制和不坚持治疗。